Acute myeloid leukemia (AML) is a fatal disease with up to 95% of patients remaining incurable. While supportive care has been increased in quantity and quality; substantial progress of AML therapy itself is still lacking. Primarily two predicaments challenge current therapy: first, the heterogeneity of the disease; second, the phenomenon of treatment resistance. Although many AML patients initially respond to therapy, the majority of patients relapse caused by chemoresistant clones, ultimately leading to the incurability of the disease^[@CR1]--[@CR3]^.

Approximately a quarter of AML patients present with FLT3-gain-of-function mutations. This usually entails a constitutive activation of FLT3 receptor downstream signaling pathways and changes gene expression patterns from healthy to malignant^[@CR4]^. On account of the poor prognosis of FLT3-ITD^+^ AML patients, FLT3-inhibitors are under development and in clinical testing. Nevertheless, acquired treatment resistance persists. This underlines the necessity of a greater knowledge on the origins of resistance as well as new approaches abrogating treatment resistance^[@CR5]^.

Therefore, we propose to deviate from the common strategy of target inhibition and focus on the reinforcement of negatively regulated downstream targets of well-known oncogenes such as FLT3-ITD.

Because microRNA (miR) expression was shown to be altered by FLT3-ITD, this group of small non-coding RNAs is of interest in this work. By binding to the 3'UTRs of mRs, miRs post-transcriptionally regulate gene expression. Thus, miRs hold key regulatory functions in processes such as hematopoiesis and leukemogenesis^[@CR6]--[@CR8]^. In accordance with this, various miRs have been shown to impact treatment resistance as well as sensitivity toward AML therapy^[@CR9]^. First clinical trials disclosed the potential of miR-inhibitors to be a promising therapeutic option^[@CR10]^. Nevertheless, no miR-based experimental drugs are currently available in AML.

Therefore, we screened for differentially expressed miRs in bone marrow mononuclear cells from healthy donors and AML patients with either FLT3-wildtype, mutations in the FLT3-tyrosine kinase domain (TKD) or FLT3-ITD mutations (Fig. [1a](#Fig1){ref-type="fig"}, Supplementary Table [1](#MOESM1){ref-type="media"}). Here, we found miR-451a to be significantly (*p* = 0.002) lower expressed in FLT3-ITD^+^ AML patients compared to healthy individuals; while among the remaining AML samples screened, miR-451a levels were lowest in FLT3-ITD patient samples (Fig. [1b](#Fig1){ref-type="fig"}). In agreement with this, we observed increasing miR-451a levels upon differentiation of human and murine hematopoietic cells (Supplementary Figure [1a-c](#MOESM1){ref-type="media"}). In addition, we analyzed the AML patient cohort of "The Cancer Genome Atlas" (TCGA)^[@CR11]^ and discovered a similar miR-451a expression distribution (Fig. [1c](#Fig1){ref-type="fig"}). In order to confirm our observations in vitro, we assessed miR-451a levels by qPCR in FLT3-ITD-transduced U937 and 32D cells (Fig. [1d,e](#Fig1){ref-type="fig"}). Indeed, a stable overexpression of FLT3-ITD led to a decrease in miR-451a levels.Fig. 1FLT3-ITD downregulates miR-451a.**a** NGS of bone marrow mononuclear cells from healthy donors and normal karyotype AML patients with FLT3-WT, FLT3-ITD or FLT3-TKD. Heatmap of the top 50 miRs differentially expressed in AML samples compared to healthy donors ranked by *p*-value. miR-451a exhibited the lowest *p*-value. **b** Median expression levels of miR-451a are lowest in FLT3-ITD^+^ AML samples. Significance was determined by Wilcoxon test (two-tailed \*\**p* \< 0.01). **c** MiR-451a expression among FLT3-WT and FLT3-ITD AML patients of the TCGA cohort. Patients depicted were of normal karyotype. Significance was determined by Wilcoxon test (two-tailed \**p* \< 0.05). **d**,**e** Transduction of U937 and 32D cells with FLT3-ITD led to significant decrease of miR-451a levels, measured by qPCR. (two-tailed *t*-test \**p* \< 0.05; \*\**p* \< 0.01). **f** MiR-451a levels of MV4;11 cells after 48 h treatment with FLT3 inhibitors quizartinib (black bars) and gilteritinib (gray bars). Both FLT3 inhibitors raised significantly miR-451a levels measured by qPCR. (two-tailed *t*-test \**p* \< 0.05; \*\**p* \< 0.01). **g** MiR-451a expression in umbilical cord blood (UCB) cells does not change upon 48 h treatment with quizartinib and gilteritinib. (two-tailed *t*-test; n.s. *p* \> 0.05). All experiments were performed at least three times

In contrast, interruption of FLT3-ITD signaling by treatment of MV4;11 cells with FLT3 inhibitors quizartinib and gilteritinib (currently evaluated in clinical trials) caused an increase in miR-451a expression (Fig. [1f](#Fig1){ref-type="fig"}). As a healthy control, we treated mononuclear cells from umbilical cord blood (UCB) with quizartinib as well as gilteritinib and observed neither a significant change in miR-451a expression nor a difference in cell viability compared to the control (Fig. [1g](#Fig1){ref-type="fig"}, Supplementary Figure [2a](#MOESM1){ref-type="media"}). In addition, we demonstrated that only cells carrying FLT3-ITD were targeted by the indicated inhibitors (Supplementary Figure [1](#MOESM1){ref-type="media"}b-d, f).

Since miR-451a correlates with an increased cancer persistence as well as recurrence^[@CR12]^, we focused on the possible underlying interaction axis.

In various cancer types it was shown that mRNA of multi drug resistance protein 1 (MDR1), an ATP dependent efflux pump mediating chemoresistance, is targeted by miR-451a^[@CR12]^. Presently, nothing is known about the FLT3-ITD-miR-451a-MDR1 axis in AML. Hence, we conjectured that FLT3-ITD-induced repression of miR-451a and subsequent increase in MDR1 protein is in part responsible for the poor therapy response of FLT3-ITD^+^ AML patients. To prove this, we measured MDR1 protein amount after exogenous FLT3-ITD introduction and observed elevated MDR1 levels in FLT3-ITD transduced U937 cells by flow cytometry (Fig. [2a](#Fig2){ref-type="fig"}) and western blot (Fig. [2b](#Fig2){ref-type="fig"}). Upon treatment with quizartinib and gilteritinib, both miR-451a increment and decrease in MDR1 protein levels were detected (Fig. [2c](#Fig2){ref-type="fig"}).Fig. 2MiR-451a sensitizes FLT3-ITD^+^ cells to chemotherapy.**a** Stable transduction of U937 cells with FLT3-ITD and GFP. In comparison to the GFP control, transduced FLT3-ITD led to increased MDR1 levels in U937 cells (two-tailed *t*-test \*\*\**p* \< 0.001). **b** Western blot analysis revealed increased MDR1 protein levels in FLT3-ITD transduced U937 cells in comparison to GFP control (**c**) MV4;11 cells treated for 48 h with quizartinib and gilteritinib. Flow cytometric analysis exhibited decreased MDR1 protein levels (two-tailed *t*-test \**p* \< 0.05; \*\**p* \< 0.01). **d** Transient transfection of miR-451a resulted in enhanced sensitivity of MV4;11 cells toward cytarabine. Cell viability was measured by MTS-assay (two-tailed *t*-test \**p* \< 0.05). **e** Annexin V levels of stable miR-451a-transduced MV4;11 parental cells after 48 h treatment. Flow cytometry revealed a significant increment of Annexin V^+^ cells in miR-451a transduced cells compared to the non-silencing control (NSC) (two-tailed *t*-test \**p* \< 0.05). **f** MiR-451a abrogates treatment resistance of MV4;11-R cells. Resistant MV4;11 cells were stably transduced with miR-451a and treated for 48 h with quizartinib or gilteritinib. NSC non-silencing control (two-tailed *t*-test \**p* \< 0.05; \*\**p* \< 0.01). **g** MV4;11-R cells transduced with miR-451a showed decreased MDR1 levels compared to the NSC. All experiments were performed at least three times (two-tailed*t*-test \**p* \< 0.05). **h** Western blot analysis revealed reduced MDR1 protein levels in miR-451a transduced MV4;11-R cells in comparison to NSC control. **i** Proposed scheme of the FLT3-ITD-MDR1-miR-451a axis

To corroborate our hypothesis, we determined miR-451a levels in various cell lines and measured corresponding MDR1 expression. Here, expression of MDR1 correlated inversely with miR-451a levels in the leukemic cell lines K562, MV4;11, and U937 (Supplementary Figure [3a, b](#MOESM1){ref-type="media"}). Next, stable transduction of miR-451a in MV4;11 cells resulted in a significant decrease of MDR1 protein levels compared to the control (Supplementary Figure [3c](#MOESM1){ref-type="media"}). Furthermore, luciferase assay with the 3'UTR of MDR1 and mutated MDR1 3'UTR in MV4;11 cells verified that MDR1 is a direct target of miR-451a in the AML background (Supplementary Figure [3d](#MOESM1){ref-type="media"}).

To investigate whether miR-451a alone is sufficient to increase chemosensitivity, we transiently transfected MV4;11 cells with miR-451a followed by a treatment with cytarabine for 48 h. Via MTS assay, we detected a significant reduction of cell viability (Fig. [2d](#Fig2){ref-type="fig"}). By means of Annexin V staining and flow cytometry, we determined a significant additive effect on the percentage of apoptotic cells upon cytarabine as well as gilteritinib treatment in combination with exogenous miR-451a expression (Fig. [2e](#Fig2){ref-type="fig"}).

In pursuance of the miR-451a-induced abrogation of chemoresistance, we included the treatment-resistant subclone MV4;11-R into our research. MV4;11-R was previously established by Stölzel et al. by continuous midostaurin treatment of parental MV4;11 cells^[@CR13]^. MV4;11-R cells were shown to lack histone methyltransferase *EZH2* correlating with decreased sensitivity toward multiple drugs including cytarabine and quizartinib^[@CR14]^. In addition, we found an increased resistance toward gilteritinib in these cells (Supplementary Figure [2e](#MOESM1){ref-type="media"}). Upon treatment with either quizartinib, gilteritinib or cytarabine, cell growth was inhibited in MV4;11 parental cells, whereas MV4;11-R cells only showed decelerated growth (Supplementary Figure [2f-h](#MOESM1){ref-type="media"}). Consequently, we stably transduced MV4;11-R cells with miR-451a and observed a restored drug sensitivity toward FLT3 inhibitors quizartinib and gilteritinib (Fig. [2f](#Fig2){ref-type="fig"}). Moreover, exogenous miR-451a resulted in decreased MDR1 protein levels as measured by flow cytometry (Fig. [2g](#Fig2){ref-type="fig"}) and western blot (Fig. [2h](#Fig2){ref-type="fig"}).

As proof of principle, we were interested whether MDR1 inhibitor tariquidar was able to mimick miR-451a-mediated effects on chemoresistance toward quizartinib. Therefore, we treated MV4;11 as well as MV4;11-R cells with tariquidar in combination with quizartinib and analyzed cell viability. Here, tariquidar enhanced quizartinib-mediated effects and partially abrogated chemoresistance of MV4;11-R cells (Supplementary Figure [3e](#MOESM1){ref-type="media"}).

Overall, our data give insights into one molecular cause of the poor prognosis conferred by FLT3-ITD. We demonstrated that MDR1 expression is indirectly targeted by FLT3-ITD through miR-451a (Fig. [2i](#Fig2){ref-type="fig"}). Current treatment drafts of FLT3-ITD^+^ AML patients trend toward inhibition of FLT3-ITD function; since these encounter resistance impediments similar to the standard treatment regimen, sole inhibition appears to be insufficient. Hence, we propose to not only focus on inhibition of FLT3-ITD function but on mimicking the effects of its negatively regulated downstream targets. MiR-451a is such a negatively regulated target and was able to increase chemosensitivity by targeting MDR1 in vitro. To date, therapeutics inhibiting MDR1 failed application in medical practice, especially, due to toxicity-associated with pharmacokinetic drug interactions^[@CR15]^. Here, miR-451a as active substance may circumvent this plight and render treatment more effective. Succeeding research ought to determine how administration of miR-451a may be feasible for future therapy.
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